

From: [Katz, Linda](#)
To: [Sadrieh, Nakissa](#); [Dewan, Kapal](#); [Meyers, Beth](#)
Subject: RE: Rose Sheet | Today's News & Analysis--EWG
Date: Friday, December 16, 2016 8:19:00 AM

Where are we regarding the review of EWG's newest interest – products marketed to African Americans?

From: Sadrieh, Nakissa
Sent: Friday, December 16, 2016 8:06 AM
To: Dewan, Kapal; Meyers, Beth; Katz, Linda
Subject: RE: Rose Sheet | Today's News & Analysis--EWG

Well, to update you, ORPSS has changed the attorney on the formaldehyde reg development and I doubt that anything will now happen, at least in my lifetime. But I am open to good surprises and to I hope to be wrong in my pessimism here.

Indeed, our perseverance in everything that we have accomplished over the past 3 years, has been exemplary. I feel that we have done a good job of building on work started before I came to OCAC, and we have continued to have impact and influence policy development. This will not stop, despite challenges that we face now, and that we will continue to face. We cannot let these bumps in the road slow us down.

From: Dewan, Kapal <Kapal.Dewan@fda.hhs.gov>
Date: December 16, 2016 at 7:45:48 AM EST
To: Katz, Linda <Linda.Katz@fda.hhs.gov>, Meyers, Beth <Beth.Meyers@fda.hhs.gov>, Sadrieh, Nakissa <Nakissa.Sadrieh@fda.hhs.gov>
Subject: RE: Rose Sheet | Today's News & Analysis--EWG

Thanks Beth.

This news covers a number of topics. Also, mentions of “FDA did issue warning letters to Brazilian Blowout manufacturer GIB LLC and GK Hair Taming System with JUVEXIN manufacturer Van Tiboli Corp. in 2011 and 2015, respectively, stating that the products were adulterated due to high levels of methylene glycol and misbranded for inadequate or misleading labeling.”

FYI- This WL was issued with great pain but with our determination to follow through the case. This makes me feel that at times our persistence, even though not supported by OC, is worth putting that time and effort.
